Crossref
Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis
Future Prescriber · 2012
DOI: 10.1002/fps.100 ↗At a glance
Journal article in Future Prescriber, 2012. Written by Adam Mead.
Abstract (original language)
Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.
Cite
APA
Mead, A. (2012). Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. https://doi.org/10.1002/fps.100
Vancouver
Mead A. Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. 2012. doi:10.1002/fps.100
BibTeX
@article{Mead2012,
author = {Mead, Adam},
title = {Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis},
journal = {Future Prescriber},
year = {2012},
doi = {10.1002/fps.100}
}
EUVIMED